Description:
- New use for an FDA approved therapeutic with established safety profile in patients with Sjögren's syndrome
Abstract
USC researchers have developed a customizable platform able USC researchers demonstrated that rapamycin shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögren’s syndrome.
The researchers also developed rapamycin-binding protein polymer nanoparticles that exhibit potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögren’s syndrome.
The effects of the rapamycin formulation on inflamed lacrimal glands was evaluated in a non-obese diabetic mouse (NOD), a classic mouse model of SjS.
Benefit
Market Application
Market Opportunity:
Sjögren's syndrome (SjS) is an age-related chronic inflammatory disease that affects up to 4 million people in the United States. These patients suffer from dry eye disease caused by lacrimal gland inflammation. Conventional treatment is based on management of symptoms and there is a shortage of therapies that address the underlying causes of inflammation at source exocrine tissue.
Applications:
- New application for established drug in patients with Sjögren’s syndrome
Publications
Hamm-Alvarez, J Control Release. 2013 Nov 10;171(3):269-79
Other
Status: Issued US patent 9,687,523
Stage of Development:
- Studied in a relevant animal model
- Formulation developed